Moderna (NASDAQ:MRNA) Earns “Market Perform” Rating from William Blair

William Blair restated their market perform rating on shares of Moderna (NASDAQ:MRNA) in a research report report published on Thursday, RTT News reports.

A number of other analysts have also weighed in on the stock. Jefferies Financial Group reaffirmed a buy rating and set a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Oppenheimer boosted their price target on shares of Moderna from $163.00 to $179.00 and gave the stock an outperform rating in a research note on Wednesday, June 12th. Canaccord Genuity Group boosted their price target on shares of Moderna from $91.00 to $106.00 and gave the stock a hold rating in a research note on Friday, May 3rd. Royal Bank of Canada boosted their price target on shares of Moderna from $135.00 to $160.00 and gave the stock an outperform rating in a research note on Monday, June 3rd. Finally, Needham & Company LLC reissued a hold rating on shares of Moderna in a research note on Monday, June 3rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, Moderna presently has a consensus rating of Hold and a consensus target price of $134.02.

Moderna Stock Performance

Moderna stock opened at $118.75 on Thursday. The firm’s 50 day simple moving average is $134.13 and its 200 day simple moving average is $111.96. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $45.51 billion, a PE ratio of -7.58 and a beta of 1.54. Moderna has a 1-year low of $62.55 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. Moderna’s revenue was down 91.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.19 EPS. As a group, analysts expect that Moderna will post -7.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 705 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total transaction of $71,860.65. Following the completion of the sale, the chief financial officer now owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Moderna news, CFO James M. Mock sold 705 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the completion of the transaction, the chief financial officer now directly owns 5,048 shares in the company, valued at approximately $514,542.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 648 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total transaction of $105,280.56. Following the completion of the transaction, the chief financial officer now owns 5,726 shares of the company’s stock, valued at $930,303.22. The disclosure for this sale can be found here. Insiders sold 411,255 shares of company stock valued at $56,118,931 in the last quarter. Company insiders own 15.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Cedar Wealth Management LLC raised its holdings in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares in the last quarter. Allworth Financial LP raised its holdings in Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares in the last quarter. TIAA Trust National Association raised its holdings in Moderna by 2.3% in the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after purchasing an additional 102 shares in the last quarter. Principle Wealth Partners LLC increased its stake in shares of Moderna by 4.3% in the 1st quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock worth $266,000 after acquiring an additional 102 shares in the last quarter. Finally, Sound Income Strategies LLC increased its stake in shares of Moderna by 17.8% in the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after acquiring an additional 115 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.